Deal Pipeline

Deal Pipeline

Reference Summary Focus Country Raising Stage
1 A Pharma company developing new therapeutics for cancer, drug-resistant infections & other life threatening diseases using a unique therapy design platform interactively building in silico small molecule libraries around key targets, creating high potency candidates with optimal ADMET properties. Oncology and Antibiotics USA $5m Preclinical
2 An anti-cancer drug development company that uses the process of autophagy to control cancers, currently focussing on lung and endometrial cancer. Oncology Spain $15m Phase I/IIa
3 A Biomed company developing standardised tests to deliver greater accuracy of molecular diagnostic platforms, hence better treatment outcomes for the patient. Oncology USA $10m Development
4 A Biopharmaceutical company focussed on producing novel drugs to tackle antimicrobial resistance, to fight infections such as MRSA. Infection USA $5m Lead optimization
5 A Biotech company focussed on discovering and developing new immuno-modulating medicines to treat immune mediated diseases. Immune-mediated disease USA $500k Phase I/II
6 A Biomed company that is working on producing a more cost-effective and efficient MRI machine in order to save patient time and money to avoid repeat scans. Medical Imaging USA $1.5m Preclinical
7 A Biotech company with products under development in autoimmune and oncology disease indications, drug products are being produced using recombinant human alpha fetoprotein. Autoimmune and Oncology Canada $20m Autoimmune - Phase II. Oncology - Preclinical
8 A Biotech company that has developed and patented a disruptive technology that can detect and trace chemicals in the air, at the level of single molecules. Diagnostics UK $1.5m Revenue generating
9 A Biotech company that has developed the first implantable, artificial-intelligence patient alerting system designed to alarm and warn patients to seek medical attention for Acute Coronary Syndrome. Cardiology USA $20m Preclinical
10 A Biotherapeutics company developing a cardiac angiogenic gene therapy technology platform for the treatment of myocardial ischemia and refractory angina, alongside other cardiac indications including cardiac syndrome X. Cardiovascular USA $20m Phase 3 Clinical Trials
11 A Pharmaceutical company developing treatment for neurodegenerative disease and hearing loss based on resolvin and protectin actions. Central Nervous System disorders USA $10m Preclinical
12 A Biotech company that has developed an anti-cancer drug that works for colon and pancreatic cancer and can also be used to reverse chemotherapy-induced peripheral neuropathy. Oncology USA $10m Phase I
13 A Therapeutics company developing a revolutionary approach to cure obesity by converting fat-storing cells into fat-burning cells. Obesity USA $20m Pre-IND
14 A Biomed company that has produced a novel, non-systemic, non-resistant antimicrobial which has multiple applications in which it defeats pathogens and the resistance phenomenon. Antimicrobial USA $10m In vivo trials & Preclinical
15 A Pharmaceutical company developing the first specific treatment for Anti-Phospholipid Syndrome using modified antibodies. Anti Phospholipid Syndrome Norway $9m Preclinical
16 A Pharmaceutical company developing a novel drug therapy for the treatment of systemic fungal infections, producing a natural product by low cost fermentation. Fungal Infection USA $1.8m Preclinical
17 A Biopharmaceutical company developing chemical entities and central nervous system active compounds that can be used to treat a variety of neurological disorders. Neurology USA $2.5m Preclinical
18 An early stage development company working on novel and revolutionary therapies for the GI Market. Lead drug candidate offers a new approach to directly heal damaged and inflamed gut tissue in patients with Crohn's Disease and ulcerative colitis. Gastrointestinal disorders USA $13m Preclinical
19 The only company worldwide that creates extracts from mRNA-rejuvenated adult human skin cells for cosmetic application. Cosmetics & Skin Rejuvenation USA $750k Preclinical
20 A Pharmaceutical company developing a chemical, histamine dihydrochloride, used to treat migraines by targeting histamine receptors associated with migraine headaches. Migraine Headaches USA $10m Phase II
21 A Biotech company developing a new technology to direct the delivery of immunotherapy, drugs and other treatments to the exact centre of a cancer lesion. Oncology USA $33m Preclinical
22 A Biopharmaceutical company focussed on harvesting and mining unculturable micro-organisms for the isolation and development of novel medicines. Microbiome USA $13m Pre IND
23 A Pharmaceutical company producing synthetic and recombinant forms of multimeric human growth hormone and increasing half life and bioactivity of tethered human growth hormone as well as working on other tethered protein treatment. Growth Hormone deficiency USA $5m Preclinical
24 A CRO with a proven history currently focused on contract development of small-to-large molecules, biosimilars and therapeutic proteins. Revenues of $10m Contract development & manufacturing Canada $3m $5m + revenues
25 A Biomed company developing neuroprotective treatment for eye diseases or conditions where the blood supply is either reduced or blocked. Neuro-ophthalmology Australia $1.2m Preclinical
26 A Diagnostics company providing Magnetocardiography, an FDA cleared functional heart test that is fast, non-invasive and hence non-carcinogenic. Radiology (Cardiac Imaging) USA $25m FDA cleared for use
27 A Biotech company producing a machine learning program used to evaluate cardiac function from any cardiac CT dataset, giving qualitative and quantitative results. Cardiovascular USA $4m Preclinical
28 A Biotech company enabling the rapid and meaningful analysis of live primary biopsy cells by utilising the ability to rapidly culture live-primary biopsy cells to disrupt personalised therapeutic development and precision diagnostics in oncology. Oncology USA $5m Preclinical
29 A Biomed company transforming the treatment of chemo-induced nausea and vomiting outcomes through transdermal patch technology. Chemo-induced Nausea and Vomiting USA $11m Formulation
30 A Pharmaceutical company that has developed a topical antiseptic formulation which manages oral dysbiosis, bacterial imbalance of plaque in the mouth. Oral Hygiene Canada $5m Phase III
31 A Pharmaceutical company using small molecule macrocycle technology for drug discovery and development in the therapeutic areas of oncology, infectious diseases and inflammation/pain. Oncology, Infectious diseases, Inflammation/pain Canada $10m Pre-revenue
32 A Pharmaceutical company developing Natural Killer (NK) cell therapy to treat cancers, via the innate immune approach. Oncology USA $10m Pre-IND
33 A Biopharmaceutical company developing new therapies based on pharmacologically active low pH acidic formulations, focussed mainly on applying the drug to attack cancer. Acidic Formulation Drugs USA $7m Preclinical
34 A Pharmaceutical company developing drugs targeting rare autoinflammatory syndromes, orphan diseases and cancers using cytokine agonists/antagonists. Autoinflammatory USA $27m Preclinical
35 A Pharmaceutical company developing therapeutic protein drugs, such as arginine degrading enzyme, with enhanced half lives and action to treat endocrine disorders, cancers and diseases in the field of ophthalmology. Endocrinology, Oncology, Ophthalmology China $10m Preclinical
36 A Health Tech company providing a dispenser of medications, vitamins and supplements, connecting the dispensing device to a mobile app which provides customers with detailed drug information Pharmacology Poland $1.5m On the market
37 A privately held drug development company with a current portfolio consists of three promising Phase 2/2a drugs covering prevention of oral mucositis in head and neck cancer, IBS-D and Nocturia. Oral mucositis, IBS-D and Nocturia USA $40m Phase II/IIa
38 A Biotech company developing a finger-port device that measures respiration rate, stress and fitness, vascular age and endothelial functioning, sleep monitoring & analysis and haemodynamic responses to arrhythmia events which is also non-invasive, pocket size and pain free. Diagnostics Israel $7m Preclinical
39 A Biomed company producing an advanced and improved ECMO (extracorporeal membrane oxygenation) machine, which is able to oxygenate and pump blood around the body through a catheter. For use in patients in critical state or during extreme operations, such as heart transplant. Cardiovascular and Critically ill Canada $5m Preclinical
40 A Pharmaceutical company developing a non-mutated neopeptide that overcomes the tumour's escape from the immune system. Cancer Immunotherapy France $5.75m Preclinical
41 A Biomed company that has developed biological compounds that can act as blocking agents for cytokines identified to be present in cancer. Pancreatic Cancer Canada $4m Phase I
42 A Biomed company looking to reduce the global incidence of surgical & healthcare-associated infections by increasing the prevalence of surgical instrument sterilisation using nitrogen dioxide gas-based technology in lower-resource health settings without electricity and at room temperature. Surgical and healthcare-associated Infection USA $2m Launch phase
43 A Life sciences company providing a portable and compact device that performs bedside viscoelastic coagulation testing (VCT) diagnostics (near the patient). Diagnostics USA $10m Commercialisation
44 A Biomed company that is selling a product developed from pine bark that consists of natural antioxidant and anti-inflammatory compounds and is beneficial for cardiovascular health, ageing, metabolism among many others. Health Supplement New Zealand $6m Distributed
45 A privately held Pharma company focused on the development of small molecule therapeutics for oncology orphan diseases. Oncology orphan diseases USA $10m Phase I/II ready
46 A Pharmaceutical company developing cancer vaccines that stimulate the body's immune system to recognise tumour cells as non-self and so attack them and kill the cancer. Oncology Singapore/USA $5m Preclinical
47 A Pharmaceutical company developing non-addictive endocannabinoid-boosting therapeutic for pain management, PTSD and substance abuse. Pain management & diseases of CNS USA $3m Preclinical
48 A Pharmaceutical company developing a peptide that delivers protein and protein complexes into cells to treat a range of eye, heart, lung and skin diseases. Protein delivery Canada $5m Preclinical
49 A Biomed company incorporating long-term antimicrobial protection into polymer materials for dental protection to prevent dental disease. Dental USA $7m Distribution
50 A Biopharmaceutical company developing novel difficult-to-synthesise molecules and involving semisynthetic, innovative drug delivery systems. Drug delivery China $1.5m Preclinical
51 A Biomed company providing rapid next generation DNA sequencing for infectious diseases to identify pathogens such as bacteria, fungi and viruses in a rapid, precise and affordable manner. DNA sequencing USA $20m Preclinical
52 A Biopharmaceutical company developing compounds that inhibit the accumulation of harmful substances, inflammation and scarring to treat cardiovascular and metabolic diseases. Cardiovascular & Metabolic USA $6.5m Preclinical
53 A Healthcare information services company that offers free genetic healthcare information for performing a genetic exam and additional information on predispositions and a compelling call to action Healthcare information services USA $1m Phase I
54 A Biomed company developing human vaccines based on a unique, proprietary, patented platform with an extensive safety profile. Vaccinations USA $10m Preclinical
55 A Pharmaceutical company developing therapeutic drugs to target and inhibit abnormal STAT3 in cancers, present in at least 60% of all human malignancies. Oncology USA $3m Phase I
56 A Biotech company focused on treating liver disease with a novel drug that has been developed to interrupt the progression of the disease earlier in the inflammatory chain. Hepatology USA $20m Phase II
57 A Biomed company dedicated to treating heart failure through the discovery and development of innovative targeted first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. Heart failure USA $6m Preclinical
58 A Biotech company that is providing an accurate and affordable screening tool for the early detection of heart disease. Cardiology USA $25m Phase II
59 A Biomed company that has developed a closed loop artificial pancreas system for automated glucose control in ICU patients. ICU USA $7m Phase II
60 A Pharmaceutical company developing monoclonal antibodies to target TIRC7 molecules residing in inflamed tissues in order to reduce harmful inflammation. Anti-inflammatory USA $15m Preclinical
61 A Biomed company producing next generation diagnostics tests for cancer with a specific set of biomarkers enabling rapid bedside testing for breast cancer. Oncology and Diagnostics USA $2m Clinical trials
62 A Diagnostics company bringing advanced IVD testing in order to affordably deliver diagnostics at the primary point-of-care facilities. Diagnostics USA $6m Distributed
63 A Pharmaceutical company focussed on developing anti-cancer drugs by providing a kinase inhibitor, mainly focussed on initially treating breast cancer. Oncology Ireland $4m Preclinical
64 A Pharmaceutical company that deploys a new and unique chemotype to generate its potential new drugs, focused on areas with a high unmet medical need and an excellent market perspective and in which a solid intellectual property position can be established. Drug development Sweden $3m Preclinical
65 A Biomed company that has developed an injectable medical device which rapidly and permanently increases fiber bonds in the tissue matrixin order to provide a mechanically stronger tear-resistant tissue, without the cost and risk of conventional surgery. Wound healing & degenerative disc disease USA $3.5m Clinical trials
66 A Biopharmaceutical company developing a new, simple treatment for food allergies with the first product candidate focusing on peanut allergy. Food allergy USA $10m Pre IND
67 A Biomed company aiming to make immune-response diagnostic testing more efficient and available, including a next-gen blood grouping and disease screening platform. Genetic Testing USA $9m Clinic read integrated hardware & software
68 A Pharmaceutical company developing a platform that allows the combination of a therapeutic agent with a targeting conjugate in order to enter and bind to cancer cell receptors. Oncology USA $500k Preclinical
69 A Pharmaceutical company dedicated to harnessing the transformative power of botanically-derived active ingredients to develop safe and effective new medicines to address human health needs. Botanical therapy USA $10m FDA approved
70 A Biotech company that has developed an online texting platform where patients text their problems and AI technology is used to ask a set of questions which will help with the instant provision of medical advice. Online Healthcare Provision USA $12m Distributed
71 A Biotech company with in vitro technology being used to revolutionise molecular biology, this allows easier diagnosis of medical conditions such as infectious diseases and cancers. Molecular Biology USA $4m Launch phase
72 A Biomedical company providing a synthetic oncolytic peptide-based drug development platform for end-stage, refractory cancer therapy. Oncology USA $20m IND
73 A Biomed company focused on the modulation of gut microbiome with targeted pro/prebiotics towards health and disease for human application. Gastroenterology & Renal USA $25m Distributed
74 A Pharmaceutical company developing a drug for pancreatic ductal adenocarcinoma treatment based on KLOTHO hormone with convenient administration route. Oncology Israel $7.5m Preclinical
75 A clinical stage Biopharma company developing a first-in-class treatment for dementia in Alzheimer's disease utilizing a mitochondrial support intervention. Dementia / Alzheimer's USA $10m Phase II ready
76 A Biomed company that has developed a drug to treat knee osteoarthritis with potential to be the first disease modifying agent ever known. Rheumatology USA $15m Phase III
77 A Biotech company that has developed a non-invasive lung sensor that is able to continuously monitor lung fluids measurement, fluid spatiality, respiratory parameters and respiratory patterns identification as well as with lung fluids. Cardiovascular and Respiratory USA $12m Clinical trials
78 A Biomed company focused on producing an oral vaccine to prevent bacterial infection exacerbations in sufferers of COPD, asthma and cystic fibrosis, also developing an oral tablet and inhaler that is anti-oxidant and anti-inflammatory for patients with chronic lung disease. Respiratory USA $40m Phase II
79 A Pharma/Biotech company developing therapeutic drug products for cancer treatment, diseases of the eye, women's health and cannabinoid pain management, utilising it's patented drug delivery platforms. Biotech and Pharma USA $10m Licensing
80 A Biomed company developing an immunotherapy technology platform with a vision to treat antibiotic resistant bacteria (Superbugs) and viral infections. Infectious disease USA $30m Preclinical
81 A Biomed company focussing on clinical stage gene therapy and the development of a therapy to increase muscle strength and prevent muscle atrophy in debilitating muscle diseases. Musculoskeletal disease USA $15m Phase II
82 A Biomed company with a focus in immuno-oncology and working on the use of Miltuximab to target and treat cancers. Oncology Australia $5m Phase I
83 A Biomed company that has developed an implant that can be used to replaced meniscus when there has been a meniscus tear/damage. Orthopaedics USA $5m Preclinical
84 A Biomed company that is delivering solutions to help patients and care providers with chronic disease management in the home, mainly focused on respiratory diseases. Chronic illness USA $2m Phase III
85 A Biomed company with a precision medicine approach to treating cancers generated by mutations in multiple genes by interrogating a patient's entire exome and hence allowing doctors to personalise treatment. Oncology USA $3m Preclinical
86 A Biotech company developing therapeutics to treat muscle disorders with a current priority to develop a therapeutic for Duchenne Muscular Dystrophy. Muscle Disease Australia $10m Preclinical and a Phase 1 Clinical Trial
87 An innovation company focused on the commercialization of revolutionary silicon-based medical nanotechnology products that address unmet clinical needs for personalized medicine. Nanotechnology/Drug delivery USA $5m Preclinical
88 A Biomed company producing potential long term treatment for hay fever through building a much stronger immune system and immune response. Allergies Canada $2m Phase I
89 A US Pharma developing the best alternative & proprietary treatments for neurodegenerative complications such as Alzheimer's & Diabetic Neuropathic Pain using botanical drugs. Neurogenerative conditions/Natural Products USA $50m Phase III
90 A Pharmaceutical company producing hormone replacement therapy in order to slow down cognitive decline in Alzheimer's disease and other dementias. Neurological (Alzheimer's) USA $5m Preclinical
91 A Biomed company that directly targets impaired neuromuscular junctions in neuromuscular diseases and nerve injury via the Agrin/LRP4/Musk pathway. Neuromuscular disease Switzerland $16m Preclinical
92 A Biotech company that has developed high quality products that contain antimicrobial technologies that are designed to reduce or eliminate infections and the spread of diseases. Antimicrobial USA $3m FDA Clearances - Antiviral & Antibacterial
93 A Life Sciences company developing a product which addresses the control of Parkinson's motor dysfunctions and the modulation of the neuro-degenerative process. Parkinson's Spain $6m Preclinical
94 A Biomed company that has produced a series of peptide analogues that target the vasoactive intestinal peptide receptor type 1, highly expressed in cancers. Oncology USA $10m Preclinical
95 An Animal Health biotech company focussed on providing animal digital health solutions to detect medical conditions, personalise medication, food and products and to monitor vet treatment effectiveness. Animal health Israel $2m Commercial
96 A Biomed company developing targeted innate host-directed immunotherapy to treat and kill cancer cells. Oncology USA $80m Phase I
97 A Biomed company focused on gene expression predictive and prognostic tests for use in personalised medicine to enable earlier detection and more effective treatment of cancer patients. Oncology USA $1.5m Preclinical
98 A Biomed company that is developing the first medical treatment for patients with spontaneous intracerebral haemorrhage, the most severe form of stroke affecting more than 1.5 million patients per year, the drug is a powerful thrombolytic agent dedicated to intracerebral use as it is non-neurotoxic with a sustained release formulation. Neurology France €15m Phase II
99 A MedTech company developing the first FDA-cleared wrist sensor for continuous monitoring of blood oxygen. Blood Oxygen monitor Israel $5m FDA cleared
100 A Biomed company that has produced a compound which highlights cancer cell viability for radiation treatment and highlights cell viability for saving ischaemic tissue. Oncology and Cardiovascular USA $10m Preclinical
101 A Biopharmaceutical company that supports China's emerging biopharmaceutical industry and is dedicated to developing the first injectable contract manufacturing organisation with a highly automated fill-and-finish, injectables manufacturing facility. Injectables Manufacturing USA $60m Seeking co-investor to construct injectable pharmaceuticals facility
102 A Pharma company developing drugs that are effective, fast-acting and non-addicting to treat people suffering from anxiety disorders. Mental Health (Anxiety) USA $5m Commercial stage (compounded), IND-enabling stage (FDA approved)
103 A Biotech company developing an accurate, point-of-care testing machine that is attached onto a smartphone, with a sample from the oral cavity being placed into the cartridge and immediate results assessing level of periodontal infection being provided. Periodontal Infection USA $10m Preclinical
104 A Biotech company delivering innovative treatments for osteoarthritis and chronic inflammatory diseases via immunotherapy and bioinformatics, basing the treatment on the patient's own immune system and targeting the IL-6 protein. Osteoarthritis and Chronic Inflammation France €1m Preclinical
105 A Biotech company that has developed a portable dental endoscope that can be used to treat dental disease and conditions. Dental USA $5m 2018 launch
106 A Biopharmaceutical company focused on peripheral nerve gene therapy and treating neurological disorders and improving patients' quality of life. Neurological disorders USA $25m Preclinical
107 A Biotech company aiming to commercialise the first fully automated, easy-to-use, AI-based decision support system to provide new, critical, patient-specific orthopaedic information. Orthopaedics Israel $5m Clinical Trials
108 A Pharmaceutical company that has developed a therapeutic combination of low dose Naltrexone accompanied by Dopaminergic antidepressants to address the unmet need of Treatment Resistant Depression and other dopamine-related diseases. Mental health USA $10m Phase IIb
109 A Biotech company that has developed an innovative, low cost, portable and rapid point-of-care platform technology for the screening of disease biomarkers in blood, the initial product uses proprietary, microfluidics technology to screen for breast cancer. Medical Screening Device USA $10m Commercial
110 A Biotech company leveraging patient communities to collect and share data to accelerate precision medicine discovery, collecting data on lifestyle, behaviour etc., via a free online mobile platform. Precision Medicine and Data Collection USA $3m Preparing public launch of mobile app
111 A R&D-stage cell therapy company providing technologies that focus on the use of tissue-specific epithelial stem cells to create novel cellular therapies and diagnostics. Cell Therapy and Diagnostics USA $15m IND
112 A clinical stage company with a specialized patented laser for improving the outcome of stem cell treatments. Stem Cell Therapy USA $10m IND
113 A Biopharmaceutical company based on a drug delivery platform in commercial phase, focussed on developing improved versions of existing drugs therefore lower development risk, less financial undertaking and the option to patent in many cases. Drug delivery Sweden $5m Commercial phase
114 A new and innovative hemostatic clotting agent that is designed to stop venous bleeding on contact and arterial haemorrhages within seconds. Coagulation (acute haemorrhage) USA $50m Clinical Trials
115 A Biomed company developing a respiratory stimulative medicine that will increase respiratory tone, to be used to prevent overdose death with intentional or accidental opioid overconsumption/overdose. Opioid Overdose USA $10m Preclinical
116 A Biomed company providing efficient transdermal and topical drug delivery technology with multiple applications, including NMDA receptor antagonist for post-surgical pain (to avoid opioid overdose) and for veterans suffering from PTSS (to prevent veteran suicide), amongst many other medicinal applications. Transdermal and Topical Drug Delivery USA $25m Phase II
117 A Biomed company developing mobile app based products in order to reduce the number of medical errors caused by 'human factors' Diagnostic, NICU, Laboratory & Management USA $5m Preclinical
118 A Biomed company with a lead product that is a specifically designed lipid emulsion antidote for non-opiate drug overdoses, delivered via an emergency kit including pre-filled syringes to simplify use, enabling fast response and greater adoption. Non-opioid Drug Overdose USA $10m Phase II
119 A Pharmaceutical company developing novel cancer immunotherapies addressing the need for combinations of therapy to overcome resistance. Oncology BVI $25m Clinical trials
120 A Biomed company developing a novel, anti-addiction oral medication that may have applications across many substance use disorders, the drug has demonstrated anti-addiction effects in the brain. Substance Addiction USA $10m Clinical
121 A Biotech company that is producing high strength spider silk fibers, identical or superior to natural fibers. The high strength, lightweight, highly durable, elasticity and biocompatibility of spider silk mean it has numerous medical and non-medical bio-applications, such as in defence, 3D printing, sporting goods, cosmetics, next-gen surgical sutures among many others. Spider silk Fiber Production Israel $10m Manufacturing
122 A Biotech company specialising in the prevention of bacterial biofilm formation in medical, dental and industrial applications using a proprietary selenium-based technology. Bacterial disease USA $2m Distribution
123 A Therapeutics company focused on developing and commercializing novel therapeutics against neglected parasitic diseases with a current priority on Chagas Disease Orphan Diseases USA $10m Preclinical
124 A Biomed company that combines proprietary nanotechnologies with structural biology to generate superior medicine with a primary focus on: cannabinoids to generate ophthalmic, neural and transdermal formulations to address large unmet clinical needs; and reformulate underperforming FDA-approved drugs that are sub-optimal due to poor water solubility and low bioavailability. Nanotechnology USA $10m Preclinical
125 A Pharmaceutical company developing a drug designed to act mechanically in the gut to help prediabetics and diabetics achieve clinically meaningful reduction in blood sugar and cholesterol levels, becoming the first and only oral prescription of its kind. Diabetes Sweden $3.5m Phase I
126 A Biotech drug repurposing and orphan disease development company focussing on CNS conditions and applying proprietary processes to orphaned and rare drug opportunities. Drug development & Orphan disease development Spain $12m Phase II
127 A privately owned, late stage Biotech company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers. Cancer Luxembourg $65m Registered for market launch in the EU
128 A Pharmaceutical company with a novel approach to drug development through epigenetic signatures proposing to differentiate tumours instead of killing them through the microscopic imaging of epigenetic landscape platform. Oncology USA $5m Preclinical
129 A Pharmaceutical company that has developed a compound that can be used orally as pills or topically as lotions or sprays to protect skin from burning and from the photoaging effects of sunlight. Skincare Canada $15m Own's rights
130 A Biomed company developing NG12 and NG13 to treat cancer therapy induced alopecia and radio-dermatitis and enhance radiotherapy and chemotherapy efficacy. Oncology China $5m Clinical trials
131 A Pharmaceutical company that has developed peptidase inhibitors that block cancer cell proliferation and survival and so induce degradation hence leading to (cancer) cell death. Oncology USA $3m Preclinical
132 A Biotech company in preclinical stage working on repurposing FDA-approved oral products for topical use to treat dermatology indications. Dermatology USA $8m Preclinical
133 A Biotech company developing novel immunotherapies for critical antibiotic-resistant infections with a lead program treating MRSA Osteomyelitis. Infectious disease USA $6.5m Preclinical
134 A Biomed company developing next-gen DNA genotyping technology to lower the cost of DNA genotyping across markets and providing actionable evidence-based Health Action Reports around many domains, including: nutrition, supplements, exercise and lifestyle. Genetic Testing USA $2m Distributed
135 A Biomed company developing a drug delivery system to reach directly into the bladder and treat diseases there, for example, specifically targeting bladder cancer. Drug delivery UK $10m Preclinical
136 A Biomed company with a mission to develop monoclonal antibody-based anti-cancer drugs and cancer therapy and developing licensing of related technology to major pharma's for commercial/clinical development. Oncology Canada $10m Preclinical
137 A Biomed company developing the Tat vaccine, a novel immunotherapy that improves clinical outcomes in HIV patients on antiretroviral therapy. Antiretroviral therapy Italy $25m Phase III
138 A Biomed company that develops revolutionary non-invasive spider and reticular vein therapy solutions, and commercialises med-tech solutions on a "Therapy As A Service" business model basis. Vascular USA $10m Pre-revenue
139 A Biomed company developing universal recombinant antivenom via single domain antibodies. Antivenom (snake bites) USA $2m Preclinical
140 A Biotech company commercialising an invented breakthrough cancer treatment that kills five cancer types via energy-based therapeutics. Oncology USA $3.5m Preclinical
141 A Biomed company that has produced advanced circulatory support fluid based on phospholipid nanoparticles, to treat hypovolemia and refractory shock. Cardiovascular USA $1m Preclinical
142 A Biomed company developing treatment for frequent episodes of urination at night through the use of patented synthesis of low dose prostaglandins. Nocturia USA $1.2m Phase III
143 A Pharmaceutical company developing treatments for orphan kidney disease, diabetic nephropathy and polycystic kidney disease using the reformulation of oxypurinol. Renal disease Canada $7m Phase II
144 A Biomed company with a library of topically applied, probiotic-like bacteria used as vehicles for targeted delivery of skin-healthy substances. Skincare/ inflammatory skin disease USA $5m Distribution ready